US Stock MarketDetailed Quotes

INMB INmune Bio

Watchlist
  • 7.140
  • +0.010+0.14%
Close May 7 16:00 ET
  • 7.140
  • 0.0000.00%
Post 16:05 ET
164.11MMarket Cap-3.38P/E (TTM)

INmune Bio Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
-90.97%14K
0
0
0
-63.16%14K
-58.56%155K
-71.13%28K
-56.12%43K
187.50%46K
-76.69%38K
Operating revenue
-90.97%14K
--0
--0
--0
-63.16%14K
-58.56%155K
-71.13%28K
-56.12%43K
187.50%46K
-76.69%38K
Cost of revenue
Gross profit
Operating expense
42.66%42.65M
12.61%9.47M
43.34%12.29M
52.78%9.87M
70.73%11.03M
13.57%29.9M
46.49%8.41M
13.66%8.57M
0.83%6.46M
-2.71%6.46M
Selling and administrative expenses
-1.45%9.48M
-11.92%2.11M
-14.19%2.22M
21.78%2.81M
0.43%2.34M
3.94%9.62M
3.05%2.4M
8.56%2.59M
4.24%2.31M
-0.17%2.33M
-General and administrative expense
-1.45%9.48M
-11.92%2.11M
-14.19%2.22M
21.78%2.81M
0.43%2.34M
3.94%9.62M
3.05%2.4M
8.56%2.59M
4.24%2.31M
-0.17%2.33M
Research and development costs
63.60%33.17M
22.41%7.35M
68.20%10.07M
70.03%7.05M
110.33%8.69M
18.78%20.27M
76.16%6.01M
16.01%5.99M
-0.98%4.15M
-4.08%4.13M
Operating profit
-43.35%-42.64M
-12.98%-9.47M
-44.07%-12.29M
-53.88%-9.87M
-71.52%-11.02M
-14.60%-29.74M
-48.51%-8.38M
-14.58%-8.53M
-0.36%-6.41M
0.85%-6.42M
Net non-operating interest income expense
Other net income (expense)
307.12%553K
958.62%249K
651.43%193K
232.22%119K
92.92%-8K
80.19%-267K
84.82%-29K
87.59%-35K
80.00%-90K
73.41%-113K
Other non- operating income (expenses)
307.12%553K
958.62%249K
651.43%193K
232.22%119K
92.92%-8K
80.19%-267K
84.82%-29K
87.59%-35K
80.00%-90K
73.41%-113K
Income before tax
-40.24%-42.08M
-9.63%-9.22M
-41.22%-12.09M
-49.92%-9.75M
-68.68%-11.03M
-9.92%-30.01M
-44.15%-8.41M
-10.85%-8.56M
4.93%-6.5M
5.32%-6.54M
Income tax
Net income
-40.24%-42.08M
-9.63%-9.22M
-41.22%-12.09M
-49.92%-9.75M
-68.68%-11.03M
-9.92%-30.01M
-44.15%-8.41M
-10.85%-8.56M
4.93%-6.5M
5.32%-6.54M
Net income continuous Operations
-40.24%-42.08M
-9.63%-9.22M
-41.22%-12.09M
-49.92%-9.75M
-68.68%-11.03M
-9.92%-30.01M
-44.15%-8.41M
-10.85%-8.56M
4.93%-6.5M
5.32%-6.54M
Minority interest income
Net income attributable to the parent company
-40.24%-42.08M
-9.63%-9.22M
-41.22%-12.09M
-49.92%-9.75M
-68.68%-11.03M
-9.92%-30.01M
-44.15%-8.41M
-10.85%-8.56M
4.93%-6.5M
5.32%-6.54M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-40.24%-42.08M
-9.63%-9.22M
-41.22%-12.09M
-49.92%-9.75M
-68.68%-11.03M
-9.92%-30.01M
-44.15%-8.41M
-10.85%-8.56M
4.93%-6.5M
5.32%-6.54M
Basic earnings per share
-26.35%-2.11
14.89%-0.4
-25.00%-0.6
-38.89%-0.5
-69.44%-0.61
-9.87%-1.67
-46.88%-0.47
-11.63%-0.48
5.26%-0.36
7.69%-0.36
Diluted earnings per share
-26.35%-2.11
14.89%-0.4
-25.00%-0.6
-38.89%-0.5
-69.44%-0.61
-9.87%-1.67
-46.88%-0.47
-11.63%-0.48
5.26%-0.36
7.69%-0.36
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue -90.97%14K000-63.16%14K-58.56%155K-71.13%28K-56.12%43K187.50%46K-76.69%38K
Operating revenue -90.97%14K--0--0--0-63.16%14K-58.56%155K-71.13%28K-56.12%43K187.50%46K-76.69%38K
Cost of revenue
Gross profit
Operating expense 42.66%42.65M12.61%9.47M43.34%12.29M52.78%9.87M70.73%11.03M13.57%29.9M46.49%8.41M13.66%8.57M0.83%6.46M-2.71%6.46M
Selling and administrative expenses -1.45%9.48M-11.92%2.11M-14.19%2.22M21.78%2.81M0.43%2.34M3.94%9.62M3.05%2.4M8.56%2.59M4.24%2.31M-0.17%2.33M
-General and administrative expense -1.45%9.48M-11.92%2.11M-14.19%2.22M21.78%2.81M0.43%2.34M3.94%9.62M3.05%2.4M8.56%2.59M4.24%2.31M-0.17%2.33M
Research and development costs 63.60%33.17M22.41%7.35M68.20%10.07M70.03%7.05M110.33%8.69M18.78%20.27M76.16%6.01M16.01%5.99M-0.98%4.15M-4.08%4.13M
Operating profit -43.35%-42.64M-12.98%-9.47M-44.07%-12.29M-53.88%-9.87M-71.52%-11.02M-14.60%-29.74M-48.51%-8.38M-14.58%-8.53M-0.36%-6.41M0.85%-6.42M
Net non-operating interest income expense
Other net income (expense) 307.12%553K958.62%249K651.43%193K232.22%119K92.92%-8K80.19%-267K84.82%-29K87.59%-35K80.00%-90K73.41%-113K
Other non- operating income (expenses) 307.12%553K958.62%249K651.43%193K232.22%119K92.92%-8K80.19%-267K84.82%-29K87.59%-35K80.00%-90K73.41%-113K
Income before tax -40.24%-42.08M-9.63%-9.22M-41.22%-12.09M-49.92%-9.75M-68.68%-11.03M-9.92%-30.01M-44.15%-8.41M-10.85%-8.56M4.93%-6.5M5.32%-6.54M
Income tax
Net income -40.24%-42.08M-9.63%-9.22M-41.22%-12.09M-49.92%-9.75M-68.68%-11.03M-9.92%-30.01M-44.15%-8.41M-10.85%-8.56M4.93%-6.5M5.32%-6.54M
Net income continuous Operations -40.24%-42.08M-9.63%-9.22M-41.22%-12.09M-49.92%-9.75M-68.68%-11.03M-9.92%-30.01M-44.15%-8.41M-10.85%-8.56M4.93%-6.5M5.32%-6.54M
Minority interest income
Net income attributable to the parent company -40.24%-42.08M-9.63%-9.22M-41.22%-12.09M-49.92%-9.75M-68.68%-11.03M-9.92%-30.01M-44.15%-8.41M-10.85%-8.56M4.93%-6.5M5.32%-6.54M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders -40.24%-42.08M-9.63%-9.22M-41.22%-12.09M-49.92%-9.75M-68.68%-11.03M-9.92%-30.01M-44.15%-8.41M-10.85%-8.56M4.93%-6.5M5.32%-6.54M
Basic earnings per share -26.35%-2.1114.89%-0.4-25.00%-0.6-38.89%-0.5-69.44%-0.61-9.87%-1.67-46.88%-0.47-11.63%-0.485.26%-0.367.69%-0.36
Diluted earnings per share -26.35%-2.1114.89%-0.4-25.00%-0.6-38.89%-0.5-69.44%-0.61-9.87%-1.67-46.88%-0.47-11.63%-0.485.26%-0.367.69%-0.36
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion with Explanatory Notes--------Unqualified Opinion--------

Market Insights

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
JINGHAO MEDICAL
872925
+29.96%
TONGYI AEROSPACE
871642
+25.11%
ESKONJAC
839273
+21.20%
4
Jiangsu Olive Sensors High-Tech
300507
+20.05%
5
Jing-Jin Electric Technologies
688280
+20.05%
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.

Discussing

FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma Show More
FOMC Press Conference, March 19, 2025